Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Custirsen with Docetaxel and Prednisone in mCRPC
NCT00258388Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Sep 2005
- Primary completion
- Nov 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of custirsen in prostate cancer (PCa) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Prostate-Specific Antigen Response at 2 years. Started Sep 2005; status: completed.
02
Drugs
custirsen
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00258388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258388.